Welcome to Beike Biotech
Beike Biotechnology is a leading biotechnology company whose scientists have been dedicated to the development and commercialization of adult stem cell therapies since 1999. The company currently produces a full line of stem cell products derived from umbilical cord, cord blood, and bone marrow stem cells. Beike's proprietary processing and quality assurance technologies prepare the cells for use in treating a variety of serious medical conditions including ataxia, brain injury, cerebral palsy, diabetic foot disease, lower limb ischemia, multiple sclerosis, muscular dystrophy, spinal cord injury, and optic nerve damage.
Watch the video introduction to the Shenzhen Beike Biotechnology Company.
Beike's stem cells are derived from healthy donors who are carefully screened for transmissible diseases. The samples are additionally screened by government appointed blood banks and Beike’s specialized laboratories. The stem cells are then banked in state-of-the-art facilities and only utilized in partnership with the best hospitals and physicians.
New Study Finds Cord Blood-derived Stem Cell Treatments Improve Ataxia Patients' Functionality and Quality of LifeIn an Open Label Treatment Study 30 Patients with the Neurodegenerative Disorder Hereditary Ataxia Were Treated with Stem Cells Provided by Beike Biotechnology
SHENZHEN, China and SAN DIEGO, Calif., Sept. 6, 2011 /PRNewswire-Asia/ -- The Journal of Translational Medicine reports on a new study in which 30 patients with Hereditary Ataxia showed statistically significant improvements in functionality and quality of life after being treated with a combination of cord blood-derived stem cell treatments and physical therapy.
The study was conducted at the Nanshan Affiliated Hospital of Guangdong Medical College in China, and included the participation of Beike Biotechnology Company (http://www.beikebiotech.com/), China's leading stem cell research and regenerative medicine company, and the San Diego biotech company Medistem, Inc. (MEDS.PK). The peer-reviewed article is available at:http://www.translational-medicine.com/content/9/1/65.
Beike Biotechnology Upgrades Its Processing and Cryopreservation Technology to Expedite Advancements in Stem Cell Therapies
Beike and ThermoGenesis Intend to Establish a "Center of Excellence" Showcase in Taizhou City
TAIZHOU, China, March 16, 2011 /PRNewswire-Asia/ -- Beike Biotechnology Co. Ltd. ("Beike") (http://www.beikebiotech.com), China's leading stem cell research and regenerative medicine company, announced an agreement with USA-based ThermoGenesis Corp. to employ new, cutting edge stem cell processing and storage technology across its adult stem cell collection, processing, and archive platform.
Under the arrangement, which underscores Beike's strategic commitment to upgrading its current technology and clinical research capabilities, Beike becomes the first company in the People's Republic of China to secure the rights to the AXP and BioArchive Cord Blood systems. AXP® is a proprietary family of automated devices used for the processing of cord blood; the BioArchive® System is an automated cryogenic device used to archive cord blood stem cell units for transplant.
New Research Demonstrates Safety of Cord-blood-derived Stem Cell Treatments
Beike Biotechnology and Medistem, Inc. Report on 114 Patients Treated With Novel Cord Blood Stem Cell Protocol; New Approach Opens Door to Expanded Uses of Cord Blood Stem Cells
SHENZHEN, China, Sept. 2 /PRNewswire-Asia/ -- In a new peer-reviewed article published by the Journal of Translational Medicine, scientists from Beike Biotechnology ( http://www.beikebiotech.com/ ), China's leading stem cell research and regenerative medicine company, and Medistem, Inc. (Pink Sheets: MEDS; http://www.medisteminc.com ), reported positive safety data in 114 patients who were treated by doctors at Nanshan Affiliated Hospital of Guangdong Medical College (Shenzhen Nanshan Hospital) in Shenzhen using Beike's proprietary cord blood stem cell transplantation protocol.
The peer-reviewed paper is available at http://bit.ly/cBNBYt .
The report aims to serve as an "expanded Phase I" study, with efficacy data to be published in a subsequent paper. It describes biochemical, hematological, immunological, and general safety profiles of patients with neurological diseases who were observed from between one month to four years after treatment. No serious treatment-associated adverse effects were observed.
New Study Demonstrates Improvements in Lupus Patients Receiving Stem Cell Therapies
Lupus study shows promising results using umbilical cord mesenchymal stem cells.
NANJING, Jiangsu, China, June 7, 2010 /PRNewswire-Asia/ -- A new study shows that umbilical cord mesenchymal stem cell transplant (UC-MSCT) may improve symptoms and biochemical values in patients with severe refractory systemic lupus erythematosus (SLE).
In research published online (ahead of print) May 6, 2010 in Arthritis & Rheumatism, lead author and Director of Rheumatology and Immunology at Nanjing University Medical School's renowned Drum Tower Hospital Dr. Lingyun Sun and colleagues report on 16 patients with severe SLE that did not respond to standard treatments. All 16 patients received stem cell transplants. Ten patients completed at least 6 months of follow-up and 2 patients were followed for more than 2 years. There was no treatment-related mortality or other adverse event during or after UC-MSCT, according to the article.
- Beike Biotechnology Opens First Chinese Rehabilitation Center in Romania
- Beike Biotech Launches New International Stem Cell Venture
- Beike Biotechnology Opens World's Largest Stem Cell Storage and Processing Facility
- Beike Biotechnology Receives International Recognition for Quality Control Processes
- Beike Biotechnology, Jiangsu University and Nanjing Drum Tower Hospital Receive $1.8 Million for Human Mesenchymal Stem Cell R&D and Clinical Trials
- Beike CSO Speaks at IPA Diabetic Foot Care Conference, India